Roche Bid Could Alter Pharma's DNA
"In considering Genentech's potential frame of reference for assessing valuation in an acquisition and formulating a counter proposal, we would suggest that a comparable 30x 2009E EPS multiple to large-cap peer Celgene would support a $120 (-per-share) purchase price, that a more typical 35-60% 30-day premium seen in other acquisitions would support a $104-123 purchase price, that a 50-100% premium to our PharmaPipelines NPV of $70 could support a purchase price of $105-140 and that a comparable 10.7x sales multiple afforded MedImmune by AstraZeneca could support a purchase price of $131," the firm said in a note to clients.
"Overall, we believe that $120/share would be a reasonable counter proposal by DNA and that assuming an equitable negotiation would suggest a compromise price of $105/share, in line with a 50% premium to our PharmaPipelines NPV."
The End of an Era
Roche is saying that it will allow Genentech to operate as an independent entity with minimal interference from headquarters in Basel. In fact, Roche's presence in the U.S. will be rebranded under the Genentech name. (A smart move.) Still, will Genentech, under Roche, be given free rein to continue working with its smaller, biotech partners?What happens to the drug development partnerships with Curis (CRIS), Immunogen (IMGN) and Seattle Genetics (SGEN), for example? If Roche is true to its word, Genentech will be free to pursue its early-stage drug development with the same freedom it has today, which bodes well for the existing partnerships, hopefully. Genentech makes up 39% of the assets in the Biotech HOLDRs (BBH) exchange-traded fund. What happens when Genentech disappears as a separate, publicly traded company.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV